UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 1, 2018

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES X

NO ___

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES X

NO ___

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___ Emerging growth company ___

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ___

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ____

NO X

At May 7, 2018, 5,849,571,048 shares of the issuer s voting common stock were outstanding.

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three months ended April 1, 2018 and April 2, 2017

Condensed Consolidated Statements of Comprehensive Income for the three months ended April 1, 2018 and April 2, 2017

Condensed Consolidated Balance Sheets as of April 1, 2018 and December 31, 2017

Condensed Consolidated Statements of Cash Flows for the three months ended April 1, 2018 and April 2, 2017

Notes to Condensed Consolidated Financial Statements

10

Review Report of Independent Registered Public Accounting Firm

49

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

50

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

105

Item 4.

Controls and Procedures

105

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

106

Item 1A.

Risk Factors

106

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

107

Item 3.

Defaults Upon Senior Securities

107

Item 4.

Mine Safety Disclosures

107

Item 5.

Other Information

107

Item 6.

Exhibits

108

Signature

109

GLOSSARY OF DEFINED TERMS

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:

2017 Financial Report

Financial Report for the fiscal year ended December 31, 2017, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2017

2017 Form 10-K

Annual Report on Form 10-K for the fiscal year ended December 31, 2017

ACA (Also referred to as U.S. Healthcare Legislation)

U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act

ACIP

Advisory Committee on Immunization Practices

ALK

anaplastic lymphoma kinase

Alliance revenues

Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

Anacor

Anacor Pharmaceuticals, Inc.

AOCI

Accumulated Other Comprehensive Income

Astellas

Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.

ASU

Accounting Standards Update

ATM-AVI

aztreonam-avibactam

Avillion

Avillion LLP

BMS

Bristol-Myers Squibb Company

BRCA

BReast CAncer susceptibility gene

CDC

U.S. Centers for Disease Control and Prevention

Citibank

Citibank N.A.

CML

chronic myelogenous leukemia

Developed Markets

U.S., Western Europe, Japan, Canada, Australia, South Korea, Scandinavian countries, Finland and New Zealand

EEA

European Economic Area

EH

Essential Health

EMA

European Medicines Agency

Emerging Markets

Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey

EPS

earnings per share

EU

European Union

Exchange Act

Securities Exchange Act of 1934, as amended

FASB

Financial Accounting Standards Board

FDA

U.S. Food and Drug Administration

GAAP

Generally Accepted Accounting Principles

GIST

gastrointestinal stromal tumors

GPD

Global Product Development

HER2-

human epidermal growth factor receptor 2-negative

hGH-CTP

human growth hormone

HIS

Hospira Infusion Systems

Hisun Pfizer

Hisun Pfizer Pharmaceuticals Company Limited

Hospira

Hospira, Inc.

HR+

hormone receptor-positive

ICU Medical

ICU Medical, Inc.

IH

Innovative Health

IPR&D

in-process research and development

IRS

U.S. Internal Revenue Service

IV

intravenous

Janssen

Janssen Biotech Inc.

J&J

Johnson & Johnson Corp.

King

King Pharmaceuticals, Inc.

LDL

low density lipoprotein

LEP

Legacy Established Products

LIBOR

London Interbank Offered Rate

Lilly

Eli Lilly & Company

LOE

loss of exclusivity

MCC

Merkel Cell Carcinoma

MCO

Managed Care Organization

MD&A

Management s Discussion and Analysis of Financial Condition and Results of Operations

Medivation

Medivation, Inc.

Merck

Merck & Co., Inc.

Meridian

Meridian Medical Technologies, Inc.

Moody s

Moody s Investors Service

NDA

new drug application

NovaQuest

NovaQuest Co-Investment Fund V, L.P.

NSCLC

non-small cell lung cancer

NYSE

New York Stock Exchange

OPKO

OPKO Health, Inc.

OTC

over-the-counter

PARP

poly ADP ribose polymerase

PBM

Pharmacy Benefit Manager

Pharmacia

Pharmacia Corporation

PP&E

Property, plant & equipment

Quarterly Report on Form 10-Q

Quarterly Report on Form 10-Q for the quarterly period ended April 1, 2018

RCC

renal cell carcinoma

R&D

research and development

RPI

RPI Finance Trust

Sandoz

Sandoz, Inc., a division of Novartis AG

SEC

U.S. Securities and Exchange Commission

SFJ

SFJ Pharmaceuticals Group

Shire

Shire International GmbH

SIP

Sterile Injectable Pharmaceuticals

S&P

Standard and Poor s

StratCO

Strategy and Commercial Operations

Tax Cuts and Jobs Act or TCJA

H.R.1, An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018

U.K.

United Kingdom

U.S.

United States

VAI

Voluntary Action Indicated

ViiV

ViiV Healthcare Limited

WRD

Worldwide Research and Development

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

April 1,

2018

April 2,

2017

Revenues

12,906

12,779

Costs and expenses:

Cost of sales(a)

2,563

2,468

Selling, informational and administrative expenses(a)

3,412

3,315

Research and development expenses(a)

1,743

1,716

Amortization of intangible assets

1,196

1,186

Restructuring charges and certain acquisition-related costs

43

84

Other (income)/deductions net

(178

60

Income from continuing operations before provision for taxes on income

4,127

3,951

Provision for taxes on income

556

821

Income from continuing operations

3,571

3,130

Discontinued operations net of tax

(1

Net income before allocation to noncontrolling interests

3,570

3,130

Less: Net income attributable to noncontrolling interests

Net income attributable to Pfizer Inc.

3,561

3,121

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.60

0.52

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.60

0.52

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.59

0.51

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.59

0.51

Weighted-average shares basic

5,957

6,006

Weighted-average shares diluted

6,057

6,092

Cash dividends paid per common share

0.34

0.32

(a)

Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

(MILLIONS OF DOLLARS)

April 1,

2018

April 2,

2017

Net income before allocation to noncontrolling interests

3,570

3,130

Foreign currency translation adjustments, net

758

228

Reclassification adjustments

15

773

228

Unrealized holding losses on derivative financial instruments, net

(114

(9

Reclassification adjustments for (gains)/losses included in net income(a)

44

(241

(69

(251

Unrealized holding gains on available-for-sale securities, net

160

150

Reclassification adjustments for (gains)/losses included in net income(a)

(174

137

Reclassification adjustments for unrealized gains included in Retained earnings(b)

(462

(476

287

Benefit plans: actuarial gains, net

163

Reclassification adjustments related to amortization

62

163

Reclassification adjustments related to settlements, net

37

52

Other

(86

45

175

261

Benefit plans: prior service (costs)/credits and other, net

Reclassification adjustments related to amortization

(46

(45

Reclassification adjustments related to curtailments, net

(7

(7

Other

(51

(52

Other comprehensive income, before tax

352

474

Tax provision on other comprehensive (loss)/income

432

25

Other comprehensive (loss)/income before allocation to noncontrolling interests

(80

449

Comprehensive income before allocation to noncontrolling interests

3,490

3,579

Less: Comprehensive income attributable to noncontrolling interests

10

15

Comprehensive income attributable to Pfizer Inc.

3,480

3,563

(a)

Reclassified into Other (income)/deductions net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Cost of sales, see Note 7F. Financial Instruments: Derivative Financial Instruments and Hedging Activities.

(b)

For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS OF DOLLARS)

April 1,

2018

December 31,

2017

(Unaudited)

Assets

Cash and cash equivalents

2,302

1,342

Short-term investments

9,119

18,650

Trade accounts receivable, less allowance for doubtful accounts: 2018 $597; 2017 $584

9,452

8,221

Inventories

8,148

7,578

Current tax assets

3,624

3,050

Other current assets

2,126

2,289

Assets held for sale

64

12

Total current assets

34,835

41,141

Long-term investments

6,945

7,015

Property, plant and equipment, less accumulated depreciation: 2018 $16,665; 2017 $16,172

13,971

13,865

Identifiable intangible assets, less accumulated amortization

47,690

48,741

Goodwill

56,393

55,952

Noncurrent deferred tax assets and other noncurrent tax assets

1,883

1,855

Other noncurrent assets

2,896

3,227

Total assets

164,612

171,797

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2018 $4,763; 2017 $3,546

9,010

9,953

Trade accounts payable

3,879

4,656

Dividends payable

2,029

Income taxes payable

1,614

477

Accrued compensation and related items

1,911

2,196

Other current liabilities

10,950

11,115

Total current liabilities

27,365

30,427

Long-term debt

31,831

33,538

Pension benefit obligations, net

5,171

5,926

Postretirement benefit obligations, net

1,488

1,504

Noncurrent deferred tax liabilities

5,967

3,900

Other taxes payable

16,605

18,697

Other noncurrent liabilities

5,644

6,149

Total liabilities

94,071

100,141

Commitments and Contingencies

Preferred stock

21

21

Common stock

465

464

Additional paid-in capital

84,599

84,278

Treasury stock

(95,460

(89,425

Retained earnings

89,961

85,291

Accumulated other comprehensive loss

(9,402

(9,321

Total Pfizer Inc. shareholders equity

70,184

71,308

Equity attributable to noncontrolling interests

358

348

Total equity

70,541

71,656

Total liabilities and equity

164,612

171,797

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Three Months Ended

(MILLIONS OF DOLLARS)

April 1,

2018

April 2,

2017

Operating Activities

Net income before allocation to noncontrolling interests

3,570

3,130

Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:

Depreciation and amortization

1,567

1,555

Asset write-offs and impairments

35

Loss on sale of HIS net assets

37

TCJA impact(a)

(68

Deferred taxes from continuing operations

294

38

Share-based compensation expense

182

218

Benefit plan contributions in excess of expense

(692

(986

Other adjustments, net

(164

(225

Other changes in assets and liabilities, net of acquisitions and divestitures

(2,715

(2,217

Net cash provided by operating activities

1,983

1,584

Investing Activities

Purchases of property, plant and equipment

(386

(358

Purchases of short-term investments

(913

(701

Proceeds from redemptions/sales of short-term investments

6,463

2,232

Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less

4,507

3,778

Purchases of long-term investments

(605

(740

Proceeds from redemptions/sales of long-term investments

576

844

Acquisitions of businesses, net of cash acquired

(585

Other investing activities, net

25

297

Net cash provided by investing activities

9,667

4,768

Financing Activities

Proceeds from short-term borrowings

428

2,554

Principal payments on short-term borrowings

(2,493

(2,519

Net payments on short-term borrowings with original maturities of three months or less

(83

(2,110

Proceeds from issuance of long-term debt

5,273

Principal payments on long-term debt

(355

(1,253

Purchases of common stock

(6,063

(5,000

Cash dividends paid

(2,032

(1,945

Proceeds from exercise of stock options

372

313

Other financing activities, net

(495

(220

Net cash used in financing activities

(10,720

(4,907

Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents

55

21

Net increase in cash and cash equivalents and restricted cash and cash equivalents

985

1,465

Cash and cash equivalents and restricted cash and cash equivalents, beginning

1,431

2,666

Cash and cash equivalents and restricted cash and cash equivalents, end

2,416

4,131

Supplemental Cash Flow Information

Non-cash transactions:

Receipt of ICU Medical common stock(b)

428

Promissory note from ICU Medical(b)

75

Cash paid during the period for:

Income taxes

257

195

Interest

259

216

Interest rate hedges

20

32

(a)

As a result of the enactment of the TCJA in December 2017, Pfizer s 2018 Provision for taxes on income was favorably impacted by approximately $68 million, primarily related to certain tax initiatives associated with the lower U.S. tax rate as a result of the TCJA.

(b)

In connection with the sale of the HIS net assets to ICU Medical, on February 3, 2017, Pfizer received 3.2 million newly issued shares of ICU Medical common stock initially valued at $428 million and a promissory note in the amount of $75 million, which was repaid in full as of December 31, 2017. For additional information, see Note 2B. Acquisition, Sale of Hospira Infusion Systems Net Assets, Licensing Arrangement and Collaborative Arrangements: Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH).

- continued -

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheet that sum to the total of the same amounts shown in the condensed consolidated statement of cash flows:

(MILLIONS OF DOLLARS)

April 1, 2018

December 31,

2017

Cash and cash equivalents

2,302

1,342

Restricted cash and cash equivalents in Short-term investments

41

Restricted cash and cash equivalents in Long-term investments

73

Restricted cash and cash equivalents in Other current assets

14

Restricted cash and cash equivalents in Other noncurrent assets

75

Total cash and cash equivalents and restricted cash and cash equivalents shown in the condensed consolidated balance sheets

2,416

1,431

Amounts included in restricted cash represent those required to be set aside by a contractual agreement in connection with ongoing litigation or to secure delivery of Pfizer medicines at the agreed upon terms. The restriction will lapse upon the resolution of the litigation or the proper delivery of the medicines.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q.

We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.

The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three months ended February 25, 2018 and February 26, 2017. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three months ended April 1, 2018 and April 2, 2017.

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2017 Form 10-K.

We manage our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). For additional information, see Note 13 and Notes to Consolidated Financial Statements Note 18. Segment, Geographic and Other Revenue Information in Pfizer s 2017 Financial Report.

Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.

In the first quarter of 2018, as of January 1, 2018, we adopted eleven new accounting standards. See Note 1B for further information.

Our recent significant business development activities include:

On February 3, 2017, we completed the sale of our global infusion systems net assets, HIS, to ICU Medical. The operating results of HIS are included in our condensed consolidated statement of income and EH s operating results through February 2, 2017 and, therefore, our financial results, and EH s operating results, for the first quarter of 2017 reflect approximately one month of HIS domestic operations and approximately two months of HIS international operations, while our financial results, and EH s operating results, for the first quarter of 2018 do not reflect any contribution from HIS global operations.

On December 22, 2016, which fell in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca s small molecule anti-infectives business, primarily outside the U.S. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of this business, and, in accordance with our international reporting period, our financial results, EH s operating results, and cash flows for the first quarter of 2017 reflect approximately two months of the small molecule anti-infectives business acquired from AstraZeneca and our financial results, EH s operating results, and cash flows for the first quarter of 2018 reflect three months of the small molecule anti-infective business acquired from AstraZeneca.

For additional information, see Note 2 and Notes to Consolidated Financial Statements Note 2. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment in Pfizer s 2017 Financial Report.

B. Adoption of New Accounting Standards

On January 1, 2018, we adopted eleven new accounting standards. The quantitative impacts on our prior period condensed consolidated financial statements of adopting the following new standards are summarized in the tables within the section titled Impacts to our Condensed Consolidated Financial Statements, further below.

10

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Revenues We adopted a new accounting standard for revenue recognition and changed our revenue recognition policies accordingly. Generally, the previous revenue recognition standards permitted recognition when persuasive evidence of a contract existed, delivery had occurred, and the seller's price to the buyer was fixed or determinable. Under the new standard, revenue is recognized upon transfer of control of the product to our customer in an amount that reflects the consideration we expect to receive in exchange. We adopted the new accounting standard utilizing the modified retrospective method, and, therefore, no adjustments were made to amounts in our prior period financial statements. We recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of Retained earnings by $584 million on a pre-tax basis ($450 million after-tax). This amount includes $500 million (pre-tax) related to the timing of recognizing Other (income)/deductions net primarily for upfront and milestone payments on our collaboration arrangements ($394 million, pre-tax) and, to a lesser extent, product rights and out-licensing arrangements, and $84 million (pre-tax) related to the timing of recognizing Revenues and Cost of sales on product shipments. The impact of adoption did not have a material impact to our condensed consolidated statement of income for the three months ended April 1, 2018 or our condensed consolidated balance sheet as of April 1, 2018. For additional information, see Note 1C.

Financial Assets and Liabilities The new accounting standard related to the recognition and measurement of financial assets and liabilities makes the following changes to prior guidance and requires:

certain equity investments to be measured at fair value with changes in fair value now recognized in net income. However, equity investments that do not have readily determinable fair values may be measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer;

a qualitative assessment of equity investments without readily determinable fair values to identify impairment; and

separate presentation of financial assets and financial liabilities by measurement category and form of financial asset on the balance sheet or in the accompanying notes to the financial statements.

We adopted the new accounting standard utilizing the modified retrospective method, and, therefore, no adjustments were made to amounts in our prior period financial statements. We recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of Retained earnings by $462 million on a pre-tax basis ($419 million after-tax) related to the net impact of unrealized gains and losses primarily on available-for-sale equity securities, restricted stock and private equity securities. In the first quarter of 2018, we recorded net unrealized gains on equity securities of $111 million. For additional information, see Note 4 and Note 7.

Presentation of Net Periodic Pension and Postretirement Benefit Cost We adopted a new accounting standard that requires the net periodic pension and postretirement benefit costs other than the service costs be presented in Other (income)/deductions net, and that the presentation be applied retrospectively. We adopted the presentation of the net periodic benefit costs other than service costs by reclassifying these costs from Cost of sales, Selling, informational and administrative expenses, Research and development expenses and Restructuring charges and certain acquisition-related costs to Other (income)/deductions net. We elected to apply the practical expedient as it is impracticable to determine the disaggregation of the cost components for amounts capitalized within Inventories and property, plant and equipment and amortized in each of those periods. We have therefore reclassified the prior period net periodic benefit costs/(credits) disclosed in Note 10 to apply the retrospective presentation for comparative periods.

As of January 1, 2018, only service costs will be included in amounts capitalized in Inventories or property, plant and equipment, while the other components of net periodic benefit costs will be included in Other (income)/deductions net. For additional information, see Note 4 and Note 10.

Income Tax Accounting The new guidance removes the prohibition against recognizing current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to a third party, unless the asset transferred is inventory. We adopted the standard utilizing the modified retrospective method, and, therefore, no adjustments were made to amounts in our prior period financial statements. We recorded the cumulative effect of adopting the standard as an adjustment to decrease the opening balance of Retained earnings by $189 million.

Accounting for Hedging Activities The standard makes the following changes:

Permits hedge accounting for risk components in hedging relationships involving nonfinancial risk and interest rate risk;

Changes the guidance for designating fair value hedges of interest rate risk and for measuring the change in fair value of the hedged item in fair value hedges of interest rate risk;

No longer requires the separate measurement and reporting of hedge ineffectiveness, but requires the income statement presentation of the earnings effect of the hedging instrument with the earnings effect of the hedged item;

11

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Permits us to exclude the portion of the change in fair value of a currency swap that is attributable to a cross-currency basis spread from the assessment of hedge effectiveness; and

Simplifies hedge effectiveness testing.

We early adopted the new accounting standard on January 1, 2018 on a prospective basis. In the first quarter of 2018, we recorded income of $29 million in Other (income)/deductions net, whereas this item would have been classified in interest income in prior periods. For additional information, see Note 7F.

Reclassification of Certain Tax Effects from AOCI We early adopted a new accounting standard that provides guidance on the reclassification of certain tax effects from AOCI. Under the new guidance, we elected to reclassify the stranded tax amounts related to the TCJA from AOCI to Retained earnings. We adopted the new accounting standard utilizing the modified retrospective method, and recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of Retained earnings by $495 million, primarily due to the effect of the change in the U.S. Federal corporate tax rate. The impact on other stranded tax amounts related to the application of the TCJA was not material to our condensed consolidated financial statements.

Classification of Certain Transactions in the Statement of Cash Flows We retrospectively adopted an accounting standard that changed the presentation of certain information in the condensed consolidated statements of cash flows, including the classification of:

debt prepayment and extinguishment costs, resulting in an increase in Operating activities Other adjustments, net and a decrease in Financing activities Other financing activities, net of $5 million for the three months ended April 1, 2018; and

accreted interest on the settlement of commercial paper debt instruments, resulting in a decrease in Operating activities Other adjustments, net, and an increase in Financing activities Other financing activities, net of $24 million for the three months ended April 1, 2018.

The new standard also establishes guidance on the classification of certain cash flows related to contingent consideration in a business acquisition. Cash payments made soon after a business acquisition date will be classified as Investing activities, while payments made thereafter will be classified as Financing activities. Payments made in excess of the amount of the original contingent consideration liability will be classified as Operating activities. The adoption of this guidance will not have a material impact to our condensed consolidated financial statements.

Presentation of Restricted Cash in the Statement of Cash Flows We adopted, on a retrospective basis, the new accounting standard, which requires that Restricted cash and restricted cash equivalents be included with Cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the consolidated statements of cash flows. As a result, for the three months ended April 1, 2018, $25 million is presented as an increase in Cash, cash equivalents, restricted cash and restricted cash equivalents.

Definition of a Business We prospectively adopted the standard for determining whether business development transactions should be accounted for as acquisitions (or disposals) of assets or businesses. If substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, the transaction will not qualify for treatment as a business. To be considered a business, a set of integrated activities and assets must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs, without regard as to whether a purchaser could replace missing elements. In addition, the definition of the term output has been narrowed to make it consistent with the updated revenue recognition guidance. In the first quarter of 2018, there was no impact to our condensed consolidated financial statements from the adoption of this new standard.

Derecognition of Nonfinancial Assets We prospectively adopted the standard, which applies to the full or partial sale or transfer of nonfinancial assets, including intangible assets, real estate and inventory. The standard provides that the gain or loss is determined by the difference between the consideration received and the carrying value of the asset. In the first quarter of 2018, there was no impact to our condensed consolidated financial statements from the adoption of this new standard.

Accounting for Modifications of Share-Based Payment Awards We prospectively adopted the standard, which clarifies that certain changes in the terms or conditions of a share-based payment award be accounted for as a modification. There was no impact to our condensed consolidated financial statements from the adoption of this new standard.

Impacts to our Condensed Consolidated Financial Statements The impacts on our prior period condensed consolidated financial statements of adopting the new standards described above are summarized in the following tables:

12

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Adoption of the standard related to pension and postretirement benefit costs impacted our prior period condensed consolidated statement of income as follows:

Three months ended April 2, 2017

(MILLIONS OF DOLLARS)

As Previously Reported

Effect of Change

Higher/(Lower)

As Restated

Cost of sales

2,470

(3

2,468

Selling, informational and administrative expenses

3,308

3,315

Research and development expenses

1,708

1,716

Restructuring charges and certain acquisition-related costs

157

(74

84

Other (income)/deductions net

(1

62

60

Income from continuing operations before provision for taxes on income

3,951

3,951

Adoption of the standards impacted our condensed consolidated balance sheet as follows:

Effect of New Accounting Standards Higher/(Lower)

(MILLIONS OF DOLLARS)

As Previously Reported Balance at December 31, 2017

Revenues

Financial Assets and Liabilities

Income

Tax Accounting

Reclassification of Certain Tax Effects from AOCI

Balance at January 1, 2018

Trade accounts receivable

8,221

13

8,234

Inventories

7,578